A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men

被引:55
作者
Herbst, KL
Coviello, AD
Page, S
Amory, JK
Anawalt, BD
Bremner, WJ
机构
[1] Charles R Drew Univ, Dept Med, Div Endocrinol Metab & Mol Med, Los Angeles, CA 90059 USA
[2] Univ Washington, Ctr Res Reprod & Contracept, Dept Med, Seattle, WA 98195 USA
[3] Dept Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98195 USA
关键词
D O I
10.1210/jc.2003-032123
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acyline is a novel GnRH antagonist that reliably inhibits gonadotropins and testosterone ( T) levels in men for 48 h after a single dose up to 75 mug/kg. In this study we examined gonadotropin and T levels in 28 healthy young men administered acyline as single doses of 150 or 300 mug/kg or serial injections of 75 mug/ kg. A single 300 mug/kg dose of acyline suppressed gonadotropins and T to castrate levels for 15 d ( baseline, 21.1 +/- 3.1; nadir, 1.95 +/- 0.4 nmol/liter; mean +/- SEM; P < 0.05). Serum acyline levels peaked 90 min after the injection of 300 mu g/kg acyline to a maximum concentration of 112.4 +/- 18 ng/ ml ( n = 7; t(1/2) = 4.9 d). Injections of 75 mu g/kg acyline every 2 d for five doses suppressed gonadotropins for more than 20 d (nadir T, 1.06 +/- 0.17 nmol/liter; P < 0.05 compared with baseline). Adverse events were mild and included erythema and pruritus at the injection site. Acyline, therefore, is one of the most potent peptide GnRH antagonists studied to date with minimal adverse events. A twice monthly injection of acyline could be used as a potent suppressor of the GnRH axis to advance the development of a hormonal male contraceptive or for treatment of hormonally dependent disease.
引用
收藏
页码:5959 / 5965
页数:7
相关论文
共 23 条
[1]   Advances in male hormonal contraception [J].
Anawalt, BD ;
Amory, JK .
ANNALS OF MEDICINE, 2001, 33 (09) :587-595
[2]   EFFECTIVE SUPPRESSION OF LUTEINIZING-HORMONE AND TESTOSTERONE BY SINGLE DOSES OF THE NEW GONADOTROPIN-RELEASING-HORMONE ANTAGONIST CETRORELIX (SB-75) IN NORMAL MEN [J].
BEHRE, HM ;
KLEIN, B ;
STEINMEYER, E ;
MCGREGOR, GP ;
VOIGT, K ;
NIESCHLAG, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (02) :393-398
[3]  
Felberbaum Ricardo E, 2002, Reprod Biomed Online, V5 Suppl 1, P68
[4]   EFFECTS OF TESTOSTERONE COBALT AND HYPOXIA ON ERYTHROPOIETIN PRODUCTION IN ISOLATED PERFUSED DOG KIDNEY [J].
FISHER, JW ;
LANGSTON, JW .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1968, 149 (A1) :75-&
[5]   AGE-RELATED ALTERATIONS IN THE STIMULATED RELEASE INVITRO OF CATECHOLAMINES AND LUTEINIZING-HORMONE-RELEASING HORMONE FROM THE MALE-RAT HYPOTHALAMUS [J].
GOLDMAN, JM ;
COOPER, RL ;
REHNBERG, GL ;
GABEL, S ;
MCELROY, WK ;
HEIN, J ;
CONN, PM .
NEUROCHEMICAL RESEARCH, 1987, 12 (07) :651-657
[6]   Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix [J].
Halmos, G ;
Schally, AV ;
Pinski, J ;
VadilloBuenfil, M ;
Groot, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) :2398-2402
[7]   Acyline: The first study in humans of a potent, new gonadotropin-releasing hormone antagonist [J].
Herbst, KL ;
Anawalt, BD ;
Amory, JK ;
Bremner, WJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (07) :3215-3220
[8]   Gonadotropin-releasing-hormone-receptor antagonists [J].
Huirne, JAF ;
Lambalk, CB .
LANCET, 2001, 358 (9295) :1793-1803
[9]   Identification and determination of GnRH antagonist gelling at injection site [J].
Jiang, G ;
Gavini, E ;
Dani, BA ;
Murty, SB ;
Schrier, B ;
Thanoo, BC ;
DeLuca, PP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 233 (1-2) :19-27
[10]   Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats [J].
Kovacs, M ;
Schally, AV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (21) :12197-12202